SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Akanda Corp. is a cannabis cultivation, manufacturing, and distribution company, which engages in the provision of premium quality and ethically sourced medical cannabis products to patients. The company cultivates and processes natural cannabis at facilities in the Kingdom of Lesotho, Africa and intend to supply medicinal-grade cannabis biomass, cannabis flower, and cannabis concentrates to wholesalers. It also imports and sells medical cannabis-based products. The company was founded on July 16, 2021 and is headquartered in New Romney, the United Kingdom.

Akanda Corp

Akanda Corp is experiencing a parabolic rally driven by a low-float setup and intense short-squeeze dynamics that have captured the attention of retail traders. The community is actively debating the stock's long-term sustainability against its history of reverse splits and high borrowing costs, while many speculate about the potential for further explosive gains.

NIO, Inc. operates as a holding company, which engages in the design, development, manufacture, and sale of smart electric vehicles. It offers its products under the brands NIO, ONVO, and FIREFLY. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Shanghai, China.

NIO Inc - ADR

NIO Inc

NIO is trending as the community debates the impact of recent delivery numbers and the launch of the new L80 model against a backdrop of ongoing short-seller activity. While some investors focus on strong year-over-year delivery growth and infrastructure expansion, others remain critical of the stock's performance and perceived manipulation by market makers.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassian shares are surging after delivering a strong quarterly earnings beat, fueling investor optimism that the enterprise software sector may be bottoming out. The community is actively debating if this performance signals a broader recovery for SaaS companies or if it remains a tactical bounce amid ongoing concerns over AI-driven disruption.

iSpecimen, Inc. is a healthcare organization that engages in procurement of human biospecimen. It collects biofluids, human tissue, hematopoietic stem, and immune cells. The company was founded by Christopher Ianelli in 2009 and is headquartered in Woburn, MA.

iSpecimen Inc

iSpecimen Inc. is attracting significant community attention due to its status as a low-float stock experiencing intense volatility, with retail investors closely monitoring for a potential short squeeze amid rumors of strategic acquisitions. Community sentiment is deeply polarized, with active debates centered on the company's long-term viability, upcoming delisting concerns, and the high-conviction participation of retail traders hoping to replicate past momentum spikes.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

Cleanspark is seeing heightened investor attention as market sentiment shifts toward energy-linked data center infrastructure, with the community closely tracking potential AI/HPC partnership announcements. While bullish sentiment centers on the company's aggressive power footprint and infrastructure expansion, short interest remains a significant talking point, fueling active speculation around a potential short squeeze.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strive Inc. is trending as traders closely monitor its role as a leveraged Bitcoin proxy, with community discussion currently polarized between optimism over institutional accumulation and concerns regarding structural dilution. Investors remain focused on how the company's treasury strategy and dividend structure will perform in relation to broader Bitcoin price volatility.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is trending following a massive earnings beat that showcased significant revenue growth and improved monetization, leading to a surge in community discussions around potential squeeze opportunities and the stock's long-term valuation. Market participants are intensely focused on how the platform's ad engine and data licensing potential will sustain this momentum against a backdrop of high volatility and intense speculative trading.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk (SNDK) is experiencing a high-volatility "sell the news" reaction despite delivering a record-breaking earnings beat and issuing bullish guidance that underscores sustained AI-driven demand. While the community is debating whether this dip offers a strategic buying opportunity or confirms a long-overdue valuation cooling after a historic year-long rally, many investors are focused on the company's aggressive share buyback plan as a potential defensive catalyst.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart is seeing heightened community discussion as investors weigh the impact of new capital partnerships against broader sector volatility and bearish sentiment surrounding fintech. While some market participants anticipate a potential short squeeze, others remain cautious as the stock grapples with macroeconomic headwinds and lingering uncertainty regarding the company's performance in a high-rate environment.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

Investors are closely monitoring escalating geopolitical tensions in the Strait of Hormuz and a shifting conflict status with Iran, which is driving significant volatility and concerns over energy supply stability. The community is actively debating whether current stock market highs are sustainable in the face of these rising oil prices, Fed policy uncertainty, and mixed earnings reports.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Short Interest in ImageneBio, Inc. (NASDAQ:IMA) Increases By 51.7%

ImageneBio, Inc. (NASDAQ:IMA - Get Free Report) was the recipient of a large growth in short interest in April. As of April 15th, there was short interest totaling 587,281 shares, a growth of 51.7...

<ul class="summary-bullets"><li>ImageneBio said it plans to use the proceeds to support the development of IMG-007 for alopecia areata and late-stage work in atopic dermatitis.</li><li>The biotech firm is currently conducting its Phase 2b ADAPTIVE trial for IMG-007, with topline results expected in 2027.</li><li>ImageneBio will present the latest data from the study at the Annual Society for Investigative Dermatology Meeting in May.</li></ul>Shares of ImageneBio, Inc. (IMA) surged more than 24% on Monday, crossing their 50-day moving average (50-DMA) for the first time since Feb. 27, 2026, after the biotech firm announced fresh funding from institutional investors in the form of a $30 million private placement.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://in.tradingview.com/chart/teA7VKVN/?symbol=NASDAQ%3AIMA"><img src="https://news.stocktwits-cdn.com/IMA_jpg_91814193cc.webp" alt="IMA.jpg"></a>Source: TradingViewImageneBio said it plans to use the proceeds to support the development of IMG-007 for alopecia areata and late-stage work in atopic dermatitis. The deal involves the sale of pre-funded warrants to purchase over 5.7 million shares at $5.199 per share.The financing round is led by new investor Coastlands Capital, with participation from Trails Edge Capital Partners and existing backers Omega Funds and OrbiMed.<h2 class="st-heading-2">What’s The Latest On Drug To Treat Dermatitis?</h2>ImageneBio is currently conducting a Phase 2b ADAPTIVE trial for IMG-007, with topline results expected in 2027. The study, which began enrollment in mid-2025 across North America, continues to show a favorable safety and tolerability profile, as indicated by a recent blinded review. A Blinded review means the people running a clinical trial do not know which patients are receiving the treatment.IMG-007 has been well tolerated across studies involving more than 150 patients, with no serious safety concerns reported. Reported side effects have been minimal, with very low rates of mild injection-site reactions.The company has also recently submitted a protocol update to expand dosing strategies and explore more patient-friendly treatment schedules. ImageneBio will present the latest data from the study at the Annual Society for Investigative Dermatology Meeting in May.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/IMA">IMA</a> on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘extremely high’ message volumes.One bullish user said buying the stock was a “no-brainer,” comparing the company’s market cap to the funding amount.<stembedurl>https://stocktwits.com/Jimmytrader35/message/650097652</stembedurl>Another user expects the stock to climb all week.<stembedurl>https://stocktwits.com/Jimmytrader35/message/650131942</stembedurl>Year-to-date, the stock has gained around 5%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/cag-stock-crashes-to-near-17-year-lows/cZJ85DBRIun">CAG Stock Crashes To Near 17-Year Lows, But Retail Sees ‘Buying Opportunity Of A Decade’</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

IMA Stock Surges 24%, Breaks 50-DMA For First Time Since February – What's Driving The Rally?

ImageneBio shares jumped to their highest levels in more than a month after the company announced a $30 million fundraising from institutional investors.

Equity

ImageneBio $30 Million Private Placement Ignites Stock

ImageneBio shares rise after a $30 million private placement to advance IMG-007 development for atopic dermatitis and alopecia areata.read more...

ImageneBio (NASDAQ:IMA) Stock Price Down 8.5%  - Here's Why

ImageneBio (NASDAQ:IMA) Shares Down 8.5% - Here's What Happened...

Atlas Venture Life Science Advisors LLC Buys New Position in ImageneBio, Inc. $IMA

Atlas Venture Life Science Advisors LLC bought a new position in shares of ImageneBio, Inc. (NASDAQ:IMA - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F...

Wall Street Zen Upgrades ImageneBio (NASDAQ:IMA) to "Hold"

Wall Street Zen upgraded ImageneBio from a "strong sell" rating to a "hold" rating in a report on Saturday...

BML Capital Management LLC Makes New Investment in ImageneBio, Inc. $IMA

BML Capital Management LLC purchased a new position in ImageneBio, Inc. (NASDAQ:IMA - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities...

ImageneBio (NASDAQ:IMA) Shares Up 2.4% - Still a Buy?

ImageneBio (NASDAQ:IMA) Stock Price Up 2.4% - Still a Buy...

ImageneBio (NASDAQ:IMA) Trading Up 0.5% - Should You Buy?

ImageneBio (NASDAQ:IMA) Shares Up 0.5% - Here's Why...

Insider Buying: ImageneBio (NASDAQ:IMA) Director Acquires 16,000 Shares of Stock

ImageneBio, Inc. (NASDAQ:IMA - Get Free Report) Director Joseph Slattery acquired 16,000 shares of the company's stock in a transaction on Wednesday, December 24th. The shares were bought at an...

ImageneBio, Inc. is a clinical-stage biotechnology company that boldly imagines a world where patients can be free from the burden of grievous immunological/autoimmune and inflammatory (I&I) diseases. It focuses on the development of new medicines with differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The company was founded in February 2016, and is headquartered in San Diego, CA.

IMA
ImageneBio, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IMA News

IMAImageneBio, Inc.